OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Britain Courts Anthropic Amid US Defense Department Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SOUTH SAN FRANCISCO, Calif., July 27, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the second quarter ended June 30, 2017 and provide a mid-year update on August 7, 2017, after the NASDAQ market closing.
Conference Call/Webcast Information
Interested parties may access the live audio webcast of the teleconference at 5:00 p.m. ET through the Investor and News page of CytomX's website at http://ir.cytomx.com or by dialing 1-877-809-6037 and using the passcode 61956517. A replay will be available on the CytomX website or by dialing 1-855-859-2056 and using the passcode 61956517. The replay will be available from August 7, 2017, until August 14, 2017.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The Company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class cancer therapeutics against difficult-to-drug targets, such as CD166 and CD71. The Company’s lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is being evaluated in a Phase 1/2 study as part of PROCLAIM (Probody Clinical Assessment In Man), an international umbrella clinical trial program that provides clinical trial sites with access to the Company’s novel therapies under one central protocol. A Phase 1/2 clinical trial for CX-2009, a first-in-class Probody drug conjugate, targeting the highly expressed tumor antigen, CD166, is also in progress under the PROCLAIM umbrella. In addition to its wholly owned programs, CytomX is collaborating with strategic partners, including AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. BMS expects to advance its first collaboration product candidate, a Probody therapeutic targeting CTLA-4, into clinical studies in early 2018. CytomX, in collaboration with AbbVie, expects to advance the CD71-targeting Probody Drug Conjugate, CX-2029, into clinical studies in 2018. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact: Spectrum Christine Quern [email protected] 202-587-2588 Investor Contact: Trout Group Pete Rahmer [email protected] 646-378-2973
